Why this cancer-starving startup, fresh off a $47M fundraise, is hungry for competition


The company, started in late 2019, already has four clinical trials in cancer, including one targeting some of the most aggressive and deadly tumors.

Previous Viewpoint: What Oregon employers need to know about a post-Roe v. Wade world
Next Orlando Health St. Cloud Hospital names Brian Wetzel its new president